MoonLake Immunotherapeutics - Class A — Quarterly Financial Statistics (NASDAQ:MLTX) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Cash from operating activities -48.47 M-38.14 M-54.53 M-44.54 M-58.79 M -196.01 M Cash from investing activities -147.33 M56.25 M88.25 M88.4 M-29.91 M 202.99 M Cash from financing activities 150.71 K73.12 M0480 K72.39 M 146 M Free cash flow -48.65 M-38.17 M-54.53 M-44.54 M-58.79 M -196.04 M

뉴스

문레이크, IL-17 데이터에 힘입어 목표 주가 상향 - Clear Street

Clear Street raises Moonlake stock price target on IL-17 data

문레이크, axSpA 잠재력에 Cantor Fitzgerald 투자의견 재확인

Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential

문레이크, H.C. 웨인라이트 목표가 40달러로 상향

Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

문레이크, 긍정적 axSpA 임상 데이터에 주가 급등

MoonLake stock surges on positive axSpA trial data

문레이크, InvestingPro 공정가치 분석 후 63% 급등